Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024 16:05 ET | Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024 16:01 ET | Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023 16:01 ET | Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023 16:05 ET | Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
November 03, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
November 02, 2023 09:01 ET | Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
September 25, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...